NanoRepro AG's Promising H1'26 Revenue Surpasses Expectations

In its recent update, NanoRepro AG has reported a strong preliminary H1'26 revenue, showcasing a significant 26% year-over-year growth. The company achieved €13 million in sales, outpacing the anticipated €11 million, mainly driven by the surge in demand for sunscreen products from Paedi Protect during an unusually warm June. This growth aligns with NanoRepro’s efforts to establish a robust consumer health and wellness platform.

The company has reached a key milestone in optimizing processes, which could potentially shift the EBITDA margin from -11% in FY25 to an anticipated 7% in FY27. Key areas prioritized for this optimization include IT, marketing, and supply chain processes. Additionally, Kirchhain will serve as a central logistics hub, and under new CFO Mike Eckel, a harmonization of finance and back-office operations is expected to further enhance efficiencies.

NanoRepro AG has increased its FY26 sales estimate to €18.8 million, indicating strategic improvements for combined scaling efforts. Despite an expected slight compression in the FY26 EBITDA margin, projected at -0.8%, the overall setup is strategically positioned for growth. As a result of these promising developments, the recommendation to BUY remains at a raised target price of €4.4.